Researchers reported in the British Journal of Cancer that targetable molecular markers help define antiprogestin-resistant breast cancer, particularly in luminal disease where endocrine resistance undermines hormone therapies. The work identifies actionable features linked to resistance mechanisms, aiming to guide more precise targeting in difficult-to-treat populations. In a separate study focused on small cell lung cancer, researchers described how molecular profiles can guide selection between targeted and immunotherapy approaches in SCLC, a cancer marked by high heterogeneity and poor outcomes. The study positions profiling as a route to reduce one-size-fits-all treatment. For translational teams, both findings emphasize biomarker-driven stratification as a practical lever to address resistance and heterogeneity across oncology indications.